# EDGAR Filing Document

**Accession Number:** 0001838126
**File Stem:** 0001838126-23-000009
**Filing Date:** 2023-2
**Character Count:** 100171
**Document Hash:** afb4b39d758ba66344558def53597a43
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001838126-23-000009.hdr.sgml**: 20230202

**ACCESSION NUMBER**: 0001838126-23-000009

**CONFORMED SUBMISSION TYPE**: SC TO-I

**PUBLIC DOCUMENT COUNT**: 8

**FILED AS OF DATE**: 20230202

**DATE AS OF CHANGE**: 20230202

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HPS Corporate Lending Fund
- **CENTRAL INDEX KEY:** 0001838126
- **IRS NUMBER:** 876391045
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-I
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93638
- **FILM NUMBER:** 23579649

**BUSINESS ADDRESS:**
- **STREET 1:** 40 WEST 57TH STREET, 33RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019
- **BUSINESS PHONE:** 212.287.6767

**MAIL ADDRESS:**
- **STREET 1:** 40 WEST 57TH STREET, 33RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HPS Corporate Lending Fund
- **CENTRAL INDEX KEY:** 0001838126
- **IRS NUMBER:** 876391045
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-I

**BUSINESS ADDRESS:**
- **STREET 1:** 40 WEST 57TH STREET, 33RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019
- **BUSINESS PHONE:** 212.287.6767

**MAIL ADDRESS:**
- **STREET 1:** 40 WEST 57TH STREET, 33RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

<br>**<br>UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION<br>WASHINGTON, D.C. 20549**

**SCHEDULE TO<br>(Rule 13e-4)**

**<br>TENDER OFFER STATEMENT PURSUANT TO SECTION 14(D)(1) OR 13(E)(1)<br>OF THE SECURITIES EXCHANGE ACT OF 1934**

<br>**HPS Corporate Lending Fund<br>(Name of Issuer)**

**HPS Corporate Lending Fund<br>(Name of Person(s) Filing Statement)**

**Class I, Class D, Class S and Class F Shares of Beneficial Interest<br>(Title of Class of Securities)**

**40440V303 , 40440V204, 40440V105 and 40440V402 <br>(CUSIP Number of class of securities)**

**<br>Yoohyun K. Choi**

**HPS Investment Partners, LLC**

**40 West 57**<sup>th</sup> **Street, 33**<sup>rd</sup> **Floor**

**New York, NY 10019**

**<br>(Name, Address and Telephone No. of Person Authorized to Receive <br>Notices and Communications on Behalf of the Person(s) Filing Statement)<br>**

***With a copy to:***

**Richard Horowitz, Esq.**

**Dechert LLP**

**<br>Three Bryant Park, 1095 Avenue of the Americas<br>New York, NY 10036**

**February 2, 2023<br>(Date Tender Offer First Published, Sent or Given to Security Holders)**

☐&nbsp;&nbsp;&nbsp;&nbsp;Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form of Schedule and the date of its filing.

---

| | |
|:---|:---|
| &nbsp;&nbsp;Amount Previously Paid: | &nbsp;&nbsp;Filing Parties: |
| &nbsp;&nbsp;Form or Registration No.: | &nbsp;&nbsp;Date Filed: |

---

☐&nbsp;&nbsp;&nbsp;&nbsp;Check the box if the filing relates solely to preliminary communications made before commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

☐&nbsp;&nbsp;&nbsp;&nbsp;third-party tender offer subject to Rule 14d-1.

☒&nbsp;&nbsp;&nbsp;&nbsp;issuer tender offer subject to Rule 13e-4.

☐&nbsp;&nbsp;&nbsp;&nbsp;going-private transaction subject to Rule 13e-3.

☐&nbsp;&nbsp;&nbsp;&nbsp;amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐

------

**Item 1.&nbsp;&nbsp;&nbsp;&nbsp;Summary Term Sheet.**

Reference is made to the Summary Term Sheet of the Offer to Purchase (as defined below) that is attached hereto as Exhibit (a)(1)(ii) and is hereby incorporated by reference.

**Item 2.&nbsp;&nbsp;&nbsp;&nbsp;Subject Company Information.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;The name of the issuer is HPS Corporate Lending Fund (the "Fund"). The Fund is a non-diversified, closed-end management investment company that has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended (the "1940 Act"). It is organized as a Delaware statutory trust. The principal executive office of the Fund is located at 40 West 57th Street, 33<sup>rd</sup> Floor, New York, NY 10019 and the telephone number is 212-287-6767.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;The title of the securities that are the subject of the offer to purchase and the related Letter of Transmittal ("Offer to Purchase" and the tender offer made thereby, the "Offer") are Class I common shares of beneficial interest (the "Class I Shares"), Class D common shares of beneficial interest (the "Class D Shares"), Class S common shares of beneficial interest (the "Class S Shares") and Class F shares of beneficial interest (the "Class F Shares" and together with Class I Shares, Class D Shares and Class S Shares, the "Shares") or portions thereof. As of the close of business on December 31, 2022, there were 144,699,650 Shares outstanding. Subject to the conditions set forth in the Offer to Purchase, the Fund will purchase up to 7,234,983 Shares that are tendered by holders of the Fund's Shares ("Shareholders") and not withdrawn as described in the Offer to Purchase (the "Offer Amount"). The Shares subject to the Offer represent approximately 5% of the Fund's Shares outstanding as of December 31, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;Shares are not traded in any market.

**Item 3.&nbsp;&nbsp;&nbsp;&nbsp;Identity and Background of Filing Person.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;The Fund is tendering for its own Shares. The information required by this Item is set forth in Item 2(a) above. HPS Investment Partners, LLC (the "Adviser") serves as the investment manager for the Fund. The Adviser is located at 40 West 57th Street, 33<sup>rd</sup> Floor, New York, NY and its telephone number is 212-287-6767. The members of the Fund's Board of Trustees (the "Board") are Michael Patterson, Grishma Parekh, Randall Lauer, Robin Melvin and Robert Van Dore (each, a "Trustee"). The Chief Executive Officer is Michael Patterson, the Chief Financial Officer and Principal Accounting Officer is Robert Busch, the Chief Compliance Officer is Gregory MacCordy, the Secretary is Yoohyun K. Choi and the Assistant Secretary is Tyler Thorn. The Trustees and the executive officers of the Fund may be reached at the Fund's business address and phone number set forth in Item 2(a) above.

&nbsp;&nbsp;&nbsp;&nbsp;

(b)-(c)&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.

**Item 4.&nbsp;&nbsp;&nbsp;&nbsp;Terms of the Transaction.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;(1)(i)&nbsp;&nbsp;&nbsp;&nbsp;Subject to the conditions set forth in the Offer to Purchase, the Fund will purchase up to 7,234,983 that are tendered by Shareholders by 11:59 p.m., Eastern Time, on March 2, 2023 and not withdrawn as described in Item 4(a)(1)(vi).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;&nbsp;&nbsp;The purchase price of a Share (or portion thereof) tendered will be its net asset value as of March 31, 2023 or a later date determined by the Fund if the Offer is extended (in each case, the "Valuation Date"), upon the terms and subject to the conditions set forth in the Offer to Purchase. Reference is made to the Cover

------

Page, Section 2 "Offer to Purchase and Price" and Section 6 "Purchases and Payment" of the Offer to Purchase, which are incorporated herein by reference.

&nbsp;&nbsp;&nbsp;&nbsp;

Each Shareholder that tenders Shares that are accepted for purchase will be sent a letter (the "Acceptance Letter") notifying the Shareholder that the Fund has received and accepted their tender. Such Shareholder will be issued a non-interest bearing, non-transferable promissory note (the "Note") entitling the Shareholder to receive an amount equal to the value of the Shareholder's Shares accepted for purchase by the Fund determined as of the Valuation Date. The Note will be held for the Shareholder by U.S. Bancorp Fund Services, LLC (d/b/a U.S. Bank Global Fund Services), the Fund's transfer agent (the "Transfer Agent"). Forms of the Acceptance Letter and the Note are attached hereto as Exhibits (a)(1)(iv) and (a)(1)(v), respectively, and incorporated herein by reference.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;&nbsp;&nbsp;The Offer is scheduled to expire on March 2, 2023 unless extended. Reference is made to the Cover Page, Summary Term Sheet, Section 2 "Offer to Purchase and Price" and Section 5 "Withdrawal Rights" of the Offer to Purchase, which are incorporated herein by reference.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;&nbsp;&nbsp;&nbsp;Reference is made to the Cover Page, Summary Term Sheet and Section 7 "Certain Conditions of the Offer" of the Offer to Purchase, which are incorporated herein by reference.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)&nbsp;&nbsp;&nbsp;&nbsp;Reference is made to Section 5 "Withdrawal Rights" of the Offer to Purchase, which is incorporated herein by reference.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)&nbsp;&nbsp;&nbsp;&nbsp;Reference is made to the Cover Page, Section 4 "Procedure for Tenders" and Section 5 "Withdrawal Rights" of the Offer to Purchase, which are incorporated herein by reference. **Note that certain Shareholders may be required to deliver their Letter of Transmittal to their Financial Advisor (instead of directly to the Transfer Agent). All Shareholders tendering Shares should carefully review their Letter of Transmittal and follow the delivery instructions therein.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii)&nbsp;&nbsp;&nbsp;&nbsp;Reference is made to Section 4 "Procedure for Tenders" and Section 6 "Purchases and Payment" of the Offer to Purchase, which are incorporated herein by reference.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix)&nbsp;&nbsp;&nbsp;&nbsp;Reference is made to the Cover Page, Section 3 "Amount of Tender," and Section 6 "Purchases and Payment" of the Offer to Purchase, which are incorporated herein by reference.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x)&nbsp;&nbsp;&nbsp;&nbsp;Reference is made to Section 2 "Offer to Purchase and Price" of the Offer to Purchase, which is incorporated herein by reference.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi)&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii)&nbsp;&nbsp;&nbsp;&nbsp;Reference is made to Section 10 "Certain Federal Income Tax Consequences" of the Offer to Purchase, which is incorporated herein by reference.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Any Shares to be purchased from any officer, Trustee or affiliate of the Fund will be on the same terms and conditions as any other purchase of Shares. To the

------

Fund's knowledge, none of the officers, Trustees, or affiliates of the Fund intends to tender Shares in the Offer.

**Item 5.&nbsp;&nbsp;&nbsp;&nbsp;Past Contracts, Transactions, Negotiations and Agreements With Respect to the Issuer's Securities.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;The Fund's Prospectus dated January 27, 2022, as amended and/or supplemented from time to time (the "Prospectus"), provides that the Board has the discretion to determine whether the Fund will purchase Shares from Shareholders from time to time pursuant to written tenders. The Adviser expects that it will recommend to the Board that the Fund purchase Shares from Shareholders quarterly. However, the Fund is not required to conduct tender offers. The Fund does not know of any other contract, agreement, arrangement, or understanding, whether contingent or otherwise or whether or not legally enforceable, between the (i) Fund, any of the Fund's executive officers or Trustees, any person controlling the Fund, or any executive officer or director of any corporation ultimately in control of the Fund and (ii) any other person with respect to any securities of the Fund (including any contract, agreement, arrangement, or understanding concerning the transfer or the voting of any such securities, joint ventures, loan or option arrangements, puts or calls, guarantees of loans, guarantees against loss, or the giving or withholding of proxies, consents or authorizations).

**Item 6.&nbsp;&nbsp;&nbsp;&nbsp;Purposes Of This Tender Offer And Plans Or Proposals.** 

(a)-(b)&nbsp;&nbsp;&nbsp;&nbsp;Reference is made to Section 1 "Background and Purpose of the Offer" of the Offer to Purchase, which is incorporated herein by reference.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;Reference is made to Section 8 "Certain Information About the Fund" of the Offer to Purchase, which is incorporated herein by reference. Because Shares are not traded in any market, subsections (6), (7), and (8) of Regulation M-A Item 1006(c) are not applicable to the Fund.

**Item 7.&nbsp;&nbsp;&nbsp;&nbsp;Source and Amount of Funds or Other Consideration.** 

(a)-(b)&nbsp;&nbsp;&nbsp;&nbsp;Reference is made to Section 6 "Purchases and Payment" of the Offer to Purchase, which is incorporated herein by reference.

**Item 8.&nbsp;&nbsp;&nbsp;&nbsp;Interest in Securities of the Issuer.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;Based on the number of Shares outstanding as December 31, 2022, the following persons own the number of Shares indicated in the below table.

---

| | | |
|:---|:---|:---|
| **<u>Person</u>** | **<u>Shares</u>** | **<u>Percentage of the Fund's<br>Outstanding Shares</u>** |
| HPS Investment Partners, LLC | 107 | \* |
| Michael Patterson | 199203 | \* |
| Grishma Parekh | 19920 | \* |
| Scott Kapnick<sup>1</sup> | 456000 | \* |

---

\*&nbsp;&nbsp;&nbsp;&nbsp;Less than 1%.

<sup>1 &nbsp;&nbsp;&nbsp;&nbsp;</sup>Shares beneficially owned indirectly through various trusts in which Scott Kapnick holds dispositive voting and investment power. Mr. Kapnick is listed because he is deemed to have a controlling interest in the Adviser. The address for Scott Kapnick is c/o HPS Investment Partners, LLC, 40 West 57th Street, 33<sup>rd</sup> Floor, New York, NY 10019.

None of the persons listed above intends to tender any of his or her Shares in the Offer. Addresses for each of the persons listed above (except Scott Kapnick) are provided in Item 3.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Reference is made to Section 8 "Certain Information About the Fund" of the Offer to Purchase, which is incorporated herein by reference. During the past sixty (60) days, the Fund has issued to the Adviser, Trustees and officers of the Fund an aggregate of approximately 1.88 shares, including the net impact of shares issued pursuant to the Fund's dividend reinvestment plan, for net proceeds of approximately $45 to the Adviser, any Trustee or officer of the Fund, or any person controlling the Fund or the Adviser. There have been no other transactions in Shares effected during the past sixty (60) days by the Fund, the Adviser, or any Trustee or executive officer of the Fund, or any person controlling the Fund or the Adviser.

**Item 9.&nbsp;&nbsp;&nbsp;&nbsp;Persons/Assets Retained, Employed, Compensated or Used.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;No persons have been employed, retained, or are to be compensated by the Fund to make solicitations or recommendations in connection with the Offer to Purchase.

**Item 10.&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;The audited annual financial statements of the Fund dated December 31, 2021 filed with the SEC on EDGAR on January 26, 2022 are incorporated by reference. The Fund will prepare and transmit to Shareholders the audited annual financial statements of the Fund within 90 days after the close of the period for which the report is being made, or as otherwise required by the 1940 Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.

**Item 11.&nbsp;&nbsp;&nbsp;&nbsp;Additional Information.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;&nbsp;None.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;&nbsp;None.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;&nbsp;&nbsp;&nbsp;None.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;&nbsp;&nbsp;&nbsp;None.

&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;The Offer to Purchase, attached hereto as Exhibit (a)(1)(ii), is incorporated herein by reference in its entirety.

**Item 12.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;(1) (i)&nbsp;&nbsp;&nbsp;&nbsp;Cover Letter to Offer to Purchase and Letter of Transmittal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;&nbsp;&nbsp;Offer to Purchase.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;&nbsp;&nbsp;Form of Letter of Transmittal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;&nbsp;&nbsp;&nbsp;Form of Letter from the Fund to Shareholders in Connection with the Fund's Acceptance of Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;&nbsp;&nbsp;&nbsp;Form of Promissory Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)&nbsp;&nbsp;&nbsp;&nbsp;Form of Notice of Withdrawal of Tender.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;(2)-(4)&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.

------

&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;None.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.

107&nbsp;&nbsp;&nbsp;&nbsp;Filing Fee Table.

------

**SIGNATURE**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**HPS CORPORATE LENDING FUND**

By:&nbsp;&nbsp;&nbsp;&nbsp;<u>/s/ Robert Busch&nbsp;&nbsp;&nbsp;&nbsp;</u><br>Name:&nbsp;&nbsp;&nbsp;&nbsp;Robert Busch<br>Title:&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer and Principal Accounting Officer

Dated: February 2, 2023

------

**EXHIBIT INDEX**

<u>Exhibit</u>

(a)(1)(i)&nbsp;&nbsp;&nbsp;&nbsp;<u>[Cover Letter to Offer to Purchase and Letter of Transmittal.](exhibita1i-coverlettertoof.htm)</u>

(a)(1)(ii)&nbsp;&nbsp;&nbsp;&nbsp;<u>[Offer to Purchase.](exhibita1ii-offertopurchas.htm)</u>

(a)(1)(iii)&nbsp;&nbsp;&nbsp;&nbsp;<u>[Form of Letter of Transmittal.](exhibita1iii-formoflettero.htm)</u>

(a)(1)(iv)&nbsp;&nbsp;&nbsp;&nbsp;<u>[Form of Letter from the Fund to Shareholders in Connection with the Fund's Acceptance of Shares.](exhibita1iv-formofletterfr.htm)</u>

(a)(1)(v)&nbsp;&nbsp;&nbsp;&nbsp;<u>[Form of Promissory Note.](exhibita1v-formofpromissor.htm)</u>

(a)(1)(vi)&nbsp;&nbsp;&nbsp;&nbsp;<u>[Form of Notice of Withdrawal of Tender.](exhibita1vi-formofnoticeof.htm)</u>

107&nbsp;&nbsp;&nbsp;&nbsp;<u>[Filing Fee Table.](exhibita1vii-filingfeetabl.htm)</u>

## Ex-99.(A)(1)(I)

**Exhibit (a)(1)(i)**

HPS CORPORATE LENDING FUND<br>40 West 57<sup>th</sup> Street, 33<sup>rd</sup> Floor

New York, NY 10019

*If you do not want to sell your shares of beneficial<br>interest at this time, please disregard this notice.<br>This is simply a notification of the Fund's repurchase offer*

February 2, 2023

Dear Shareholder:

This letter serves to inform you of important dates relating to a repurchase offer by HPS Corporate Lending Fund (the "<u>Fund</u>"). If you are not interested in tendering your shares of beneficial interest in the Fund ("<u>Shares</u>") for repurchase at this time, please disregard this notice and take no action.

Please note that, except as described below, the sale of Shares that have been issued after April 1, 2022 will be subject to an "early repurchase deduction" (except, at the discretion of the Fund, in the case of death, divorce or qualified disability of a shareholder), which will reduce your proceeds by 2%. Shares that are issued pursuant to the Fund's distribution reinvestment plan and tendered shall not be subject to the early repurchase deduction. In addition, the sale of Shares may also be subject to income and transfer taxes.

The tender offer period will begin on February 2, 2023 and end at 11:59 p.m., Eastern Time, on March 2, 2023. The purpose of the tender offer is to provide liquidity to shareholders of the Fund. Shares may be presented to the Fund for repurchase only by tendering them during one of the Fund's announced tender offers.

If you do not wish to sell your Shares for any reason, simply disregard this notice. **No action is required if you do not wish to sell any portion of your Shares at this time.**

Should you wish to tender all or some of your Shares during this tender offer period, please complete the enclosed Letter of Transmittal and return it **by mail** to the Fund's Transfer Agent, U.S. Bancorp Fund Services, LLC (d/b/a U.S. Bank Global Fund Services) per below or as instructed in the Letter of Transmittal.

HPS Corporate Lending Fund<br>c/o U.S. Bank Global Fund Services<br>615 East Michigan Street<br>Milwaukee, WI 53202

**All Shareholders tendering Shares should carefully review their Letter of Transmittal and follow the delivery instructions therein.**

All tenders of Shares must be received in good order by the Fund's Transfer Agent by 11:59 p.m., Eastern Time, March 2, 2023.

If you have any questions, please refer to the attached Offer to Purchase document, which contains additional important information about the repurchase offer, or call the Fund's transfer agent at (888) 484-1944.

Sincerely,

HPS Corporate Lending Fund

## Ex-99.(A)(1)(Ii)

**Exhibit (a)(1)(ii)**

**HPS CORPORATE LENDING FUND<br>c/o HPS Investment Partners, LLC<br>40 West 57th Street, 33rd Floor**

**New York, NY 10019**

**Offer to Purchase Up to 7,234,983 <br>Shares of Beneficial Interest<br>Dated February 2, 2023**

**The Offer and Withdrawal Rights Will Expire at<br>11:59 p.m., Eastern Time, on March 2, 2023,<br>Unless the Offer is Extended**

To the Shareholders of HPS Corporate Lending Fund:

Subject to the terms and conditions set forth in this offer to purchase ("<u>Offer to Purchase</u>") and the related Letter of Transmittal (which together with the Offer to Purchase constitutes the "<u>Offer</u>"), HPS Corporate Lending Fund, a non-diversified, closed-end management investment company that has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended (the "<u>1940 Act</u>") and is organized as a Delaware statutory trust (the "<u>Fund</u>"), is offering to purchase up to 7,234,983 of its outstanding shares of beneficial interest (including Class I common shares of beneficial interest, Class D common shares of beneficial interest, Class F common shares of beneficial interest and Class S common shares of beneficial interest, the "<u>Shares</u>") pursuant to tenders by shareholders of the Fund ("<u>Shareholders</u>") at a price equal to the net asset value per Share as of March 31, 2023 or a later date determined by the Fund if the Offer is extended (the "Valuation Date"). This Offer is currently scheduled to expire at 11:59 p.m., Eastern Time, on March 2, 2023 (the "<u>Expiration Date</u>"), but the Fund may extend this date; if it does, the Valuation Date may be changed. This Offer is being made to all Shareholders of the Fund and is not conditioned on any minimum amount of Shares being tendered, but is subject to certain conditions described below. Shares are not traded on any established trading market.

Shareholders should realize that the value of the Shares tendered in this Offer will likely change between the most recent time net asset value was calculated and communicated to them and the Valuation Date (the relevant date for determining the value of the Shares tendered to the Fund for purposes of calculating the purchase price of such Shares) and such change could be material. The Fund generally determines the net asset value of the Shares as of the last calendar day of each month within 20 business days after the last calendar day of each month. The most recently calculated net asset value for each class of the Shares can be found by going to www.hlend.com. Shareholders should keep in mind that, if they tender Shares in a tender offer with a Valuation Date that is within the 12 month period following the initial issue date of the Shares being tendered, such Shares will be subject to an "early repurchase deduction" (described further below) of 2% of the aggregate net asset value of the Shares repurchased, except as described below. The early repurchase deduction will reduce the repurchase proceeds. For illustrative purposes, a Shareholder that acquires Shares prior to or on April 1 would not incur any early repurchase deduction for participating in a repurchase offer that has a valuation date of March 31 of the following year (or anytime thereafter). Shares that are issued pursuant to the Fund's distribution reinvestment plan and tendered shall not be subject to the early repurchase deduction.

Shareholders desiring to tender all or any portion of their Shares in accordance with the terms of the Offer should complete and sign the attached Letter of Transmittal and mail it to the Fund's transfer agent, U.S. Bancorp Fund Services, LLC (d/b/a U.S. Bank Global Fund Services) (the "<u>Transfer Agent</u>") in the manner provided for in the Letter of Transmittal and set forth in Section 4 "Procedure for Tenders" below.

------

**IMPORTANT**

*The Fund makes no recommendation to any Shareholder as to whether to tender or refrain from tendering Shares. Shareholders must make their own decisions whether to tender Shares and, if so, the portion of their Shares to tender.*

*Because each Shareholder's investment decision is a personal one, based on its financial circumstances, no person has been authorized to make any recommendation on behalf of the Fund as to whether Shareholders should tender Shares pursuant to the Offer. No person has been authorized to give any information or to make any representations in connection with the Offer other than those contained herein or in the Letter of Transmittal. If given or made, such recommendation and such information and representations must not be relied on as having been authorized by the Fund.*

*This transaction has not been approved or disapproved by the Securities and Exchange Commission or the Commodity Futures Trading Commission nor has the Securities and Exchange Commission, the Commodity Futures Trading Commission, or any state securities commission passed on the fairness or merits of such transaction or on the accuracy or adequacy of the information contained in this document. Any representation to the contrary is unlawful.*

Questions and requests for assistance and requests for additional copies of the Offer may be directed to the Transfer Agent:

HPS Corporate Lending Fund <br>c/o U.S. Bank Global Fund Services<br>615 East Michigan Street<br>Milwaukee, WI 53202<br>Tel: (888) 484-1944

------

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| <u>[SUMMARY TERM SHEET](#i89f913c4127540a0a809d576f19ba9dc_7)</u> | <u>[1](#i89f913c4127540a0a809d576f19ba9dc_7)</u> |
| [1.](#id33fa7d8d4994fa4bb5e4b37583aaa01_41289)[&nbsp;&nbsp;&nbsp;&nbsp;](#id33fa7d8d4994fa4bb5e4b37583aaa01_41289)<u>[Background and Purpose of the Offer](#id33fa7d8d4994fa4bb5e4b37583aaa01_41289)</u> | <u>[2](#i89f913c4127540a0a809d576f19ba9dc_7)</u> |
| [2.](#id33fa7d8d4994fa4bb5e4b37583aaa01_41297)[&nbsp;&nbsp;&nbsp;&nbsp;](#id33fa7d8d4994fa4bb5e4b37583aaa01_41297)<u>[Offer to Purchase and Price](#id33fa7d8d4994fa4bb5e4b37583aaa01_41297)</u> | <u>[2](#i89f913c4127540a0a809d576f19ba9dc_7)</u> |
| [3.](#id33fa7d8d4994fa4bb5e4b37583aaa01_41294)[&nbsp;&nbsp;&nbsp;&nbsp;](#id33fa7d8d4994fa4bb5e4b37583aaa01_41294)<u>[Amount of Tender](#id33fa7d8d4994fa4bb5e4b37583aaa01_41294)</u> | <u>[3](#i89f913c4127540a0a809d576f19ba9dc_7)</u> |
| [4.](#id33fa7d8d4994fa4bb5e4b37583aaa01_41290)[&nbsp;&nbsp;&nbsp;&nbsp;](#id33fa7d8d4994fa4bb5e4b37583aaa01_41290)<u>[Procedure for Tenders](#id33fa7d8d4994fa4bb5e4b37583aaa01_41290)</u> | <u>[3](#i89f913c4127540a0a809d576f19ba9dc_7)</u> |
| [5.](#id33fa7d8d4994fa4bb5e4b37583aaa01_41291)[&nbsp;&nbsp;&nbsp;&nbsp;](#id33fa7d8d4994fa4bb5e4b37583aaa01_41291)<u>[Withdrawal Rights](#id33fa7d8d4994fa4bb5e4b37583aaa01_41291)</u> | <u>[4](#i89f913c4127540a0a809d576f19ba9dc_7)</u> |
| [6.](#id33fa7d8d4994fa4bb5e4b37583aaa01_41295)[&nbsp;&nbsp;&nbsp;&nbsp;](#id33fa7d8d4994fa4bb5e4b37583aaa01_41295)<u>[Purchases and Payment](#id33fa7d8d4994fa4bb5e4b37583aaa01_41295)</u> | <u>[4](#i89f913c4127540a0a809d576f19ba9dc_7)</u> |
| [7.](#id33fa7d8d4994fa4bb5e4b37583aaa01_41288)[&nbsp;&nbsp;&nbsp;&nbsp;](#id33fa7d8d4994fa4bb5e4b37583aaa01_41288)<u>[Certain Conditions of the Offer](#id33fa7d8d4994fa4bb5e4b37583aaa01_41288)</u> | <u>[5](#i89f913c4127540a0a809d576f19ba9dc_7)</u> |
| [8.](#id33fa7d8d4994fa4bb5e4b37583aaa01_41292)[&nbsp;&nbsp;&nbsp;&nbsp;](#id33fa7d8d4994fa4bb5e4b37583aaa01_41292)<u>[Certain Information About the Fund](#id33fa7d8d4994fa4bb5e4b37583aaa01_41292)</u> | <u>[5](#i89f913c4127540a0a809d576f19ba9dc_7)</u> |
| [9.](#id33fa7d8d4994fa4bb5e4b37583aaa01_41293)[&nbsp;&nbsp;&nbsp;&nbsp;](#id33fa7d8d4994fa4bb5e4b37583aaa01_41293)<u>[Full Tender by DRIP Participants](#id33fa7d8d4994fa4bb5e4b37583aaa01_41293)</u> | <u>[6](#i89f913c4127540a0a809d576f19ba9dc_7)</u> |
| [10.](#id33fa7d8d4994fa4bb5e4b37583aaa01_41296)[&nbsp;&nbsp;&nbsp;&nbsp;](#id33fa7d8d4994fa4bb5e4b37583aaa01_41296)<u>[Certain Federal Income Tax Consequences](#id33fa7d8d4994fa4bb5e4b37583aaa01_41296)</u> | <u>[6](#i89f913c4127540a0a809d576f19ba9dc_7)</u> |
| [11.](#id33fa7d8d4994fa4bb5e4b37583aaa01_41298)[&nbsp;&nbsp;&nbsp;&nbsp;](#id33fa7d8d4994fa4bb5e4b37583aaa01_41298)<u>[Miscellaneous](#id33fa7d8d4994fa4bb5e4b37583aaa01_41298)</u> | <u>[10](#i89f913c4127540a0a809d576f19ba9dc_7)</u> |
| <u>[FINANCIAL STATEMENTS](#id33fa7d8d4994fa4bb5e4b37583aaa01_41299)</u> | <u>[10](#i89f913c4127540a0a809d576f19ba9dc_7)</u> |

---

&nbsp;&nbsp;&nbsp;&nbsp;i

------

**SUMMARY TERM SHEET**

This is a summary of the features of the Offer. To understand the Offer fully and for a more complete discussion of the terms and conditions of the Offer, you should read carefully this entire Offer to Purchase and the related Letter of Transmittal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• As disclosed in the Fund's prospectus dated January 27, 2022, as amended and/or supplemented from time to time ("<u>Prospectus</u>"), the Fund may from time to time offer to repurchase a portion of its outstanding Shares pursuant to written tenders by Shareholders. Accordingly, the Fund is offering to purchase up to 7,234,983 Shares at a price equal to their net asset value (that is, the value of the Fund's total assets minus its total liabilities, divided by outstanding Shares) determined as of March 31, 2023 or such later date as may be determined by the Fund if the Offer is extended (the "<u>Valuation Date</u>"). The Shares subject to the Offer represent approximately 5% of the outstanding Shares as of December 31, 2022. The Offer, which begins on February 2, 2023, will remain open until 11:59 p.m., Eastern Time, on March 2, 2023 (the "<u>Expiration Date</u>"). The Fund reserves the right to adjust the Valuation Date to correspond to any extension of the Offer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **All Shares issued after April 1, 2022, except for Shares issued pursuant to the Fund's distribution reinvestment plan ("<u>DRIP</u>"), that are tendered and purchased in this Offer will be subject to a 2% "early repurchase deduction." See Section 6 "Purchases and Payment".** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Shareholders may tender all or a portion of their Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If an Investor tenders Shares and the Fund purchases those Shares, the Fund will effect payment for those Shares in cash promptly after the determination of the relevant NAV per share is finalized.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Other than the early repurchase deduction described below (if applicable), the Fund does not expect to impose any charges on repurchases of Shares in the Fund.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If you tender only a portion of your Shares, you must maintain a minimum account balance of at least $1,500 as of the Valuation Date. The Fund reserves the right to purchase all your Shares in the Fund if you tender less than all of your Shares and the number of Shares you tender would cause your account in the Fund to have a value lower than the required minimum balance. The Offer is being made to all Shareholders and is not conditioned on any minimum amount of Shares being tendered.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If you are a participant in the Fund's DRIP, in the event that you elect to tender your Shares in full, and such full tender is accepted by the Fund, your participation in the DRIP will be automatically terminated as of the applicable Expiration Date, and any distributions due but not yet paid as of such date will be paid in cash on the scheduled dividend payment date. Shares that are issued pursuant to the Fund's DRIP and tendered shall not be subject to the early repurchase deduction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If the Fund accepts the tender of any of your Shares, your proceeds will be funded from one or more of the following sources: cash on hand (including cash received from investments in the Fund), borrowings and/or proceeds from the sale of portfolio holdings.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Additional repurchases will be made at such times and on such terms as may be determined by the Board of Trustees of the Fund (the "<u>Board</u>"). HPS Investment Partners, LLC, the Fund's investment adviser (the "<u>Adviser</u>"), expects that it will generally recommend to the Board that the Fund offer to repurchase a portion of its outstanding Shares four times each year, effective on or about March 31, June 30, September 30 and December 31, but the Fund is not required to make any such offer.

Following this summary is a formal notice of the Offer, which remains open until the Expiration Date, unless extended. If you elect to tender your Shares, you have the right to change your mind and withdraw your tendered Shares at any time until the Expiration Date or, if such tendered Shares have not been accepted by the Fund, at any time on or after March 30, 2023. If you would like to tender your Shares, you must complete the Letter of Transmittal enclosed with the Offer to Purchase, and return it as instructed in the Letter of Transmittal to HPS Corporate Lending Fund, c/o U.S. Bank

&nbsp;&nbsp;&nbsp;&nbsp;1

------

Global Fund Services, 615 East Michigan Street, Milwaukee, WI 53202. Your properly completed mailed Letter of Transmittal must be received prior to the Expiration Date. If you decide to tender, it is your responsibility to, and the Fund strongly recommends that you do, confirm receipt of your Letter of Transmittal with the Transfer Agent by calling (888) 484-1944, Monday through Friday, except holidays, during normal business hours of 9:00 a.m. to 5:00 p.m. (Eastern Time). **All Shareholders tendering Shares should carefully review their Letter of Transmittal and follow the delivery instructions therein.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The value of your Shares will likely change between the most recent time the net asset value was calculated and communicated to you and the Valuation Date (the date when the value of your investment will be determined for purposes of calculating the purchase price of your Shares). If you would like to obtain the estimated net asset value of your Shares, visit the Fund's website at www.hlend.com.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Please note that just as you have the right to withdraw your tender of Shares, the Fund has the right to cancel, amend or postpone this offer at any time on or before the Expiration Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.<u>Background and Purpose of the Offer</u>. The purpose of the Offer is to provide liquidity to Shareholders. Because there is no secondary trading market for Shares, the Board has determined, after consideration of various matters, that the Offer is in the best interests of Shareholders in order to provide liquidity for Shares as contemplated in the Prospectus. The Board intends to consider the continued desirability of the Fund making an offer to purchase Shares four times each year, but the Fund is not required to make any such offer.

The purchase of Shares pursuant to the Offer will have the effect of increasing the proportionate interest in the Fund of Shareholders who do not tender Shares. Shareholders who retain their Shares may be subject to increased risks that may possibly result from the reduction in the Fund's aggregate assets resulting from payment for the Shares tendered. These risks include the potential for greater volatility due to decreased diversification. A reduction in the aggregate assets of the Fund may result in Shareholders who do not tender Shares bearing higher costs to the extent that certain expenses borne by the Fund are relatively fixed and may not decrease if assets decline. These effects may be reduced or eliminated to the extent that additional purchases of Shares are made by new and existing investors from time to time, although there can be no assurances that such new or additional purchases will occur.

Shares that are tendered to the Fund in connection with the Offer, if accepted for repurchase, will be repurchased, resulting in a change in the income ratio and an increase in the expense ratios of Shares owned by Shareholders remaining in the Fund (assuming no further issuances of Shares).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.<u>Offer to Purchase and Price</u>. The Fund will purchase, upon the terms and subject to the conditions of the Offer, up to 7,234,983 of those outstanding Shares that are properly tendered by, and not withdrawn (in accordance with Section 5 "Withdrawal Rights" below) before, the Expiration Date.

The Fund reserves the right to extend, amend or cancel the Offer as described in Sections 3 and 7 below. The purchase price of a Share tendered will be its net asset value as of the Valuation Date, payable as set forth in Section 6. The Fund reserves the right to adjust the Valuation Date to correspond with any extension of the Offer.

As of the close of business on December 31, 2022, there were approximately 35,101,879 Class I Shares, 17,538,259 Class D Shares and 92,059,512 Class F Shares issued and outstanding, with a net asset value per share of $23.88 for Class I Shares, $23.88 for Class D Shares and $23.88 for Class F Shares. Shareholders may obtain monthly estimated net asset value information until the Expiration Date of the Offer at www.hlend.com. The value of the Shares tendered by Shareholders likely will change between the most recent time net asset value was calculated and communicated to you and the Valuation Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.<u>Amount of Tender</u>. Subject to the limitations set forth below, Shareholders may tender all or a portion of their Shares. If you tender only a portion of your Shares, you must maintain a minimum account balance of at least $1,500 as of the Valuation Date. The Fund reserves the right to purchase all your Shares in the Fund if you tender less than all of your Shares and the number of Shares you tender would cause your account in the Fund to have a value lower than the required minimum balance. The

&nbsp;&nbsp;&nbsp;&nbsp;2

------

Offer is being made to all Shareholders and is not conditioned on any minimum amount of Shares being tendered.

If less than 7,234,983 Shares are properly tendered pursuant to the Offer and not withdrawn, the Fund will, on the terms and subject to the conditions of the Offer, purchase all of the Shares so tendered unless the Fund elects to cancel or amend the Offer, or postpone acceptance of tenders made pursuant to the Offer, as provided in Section 7 "Certain Conditions of the Offer" below. If more than 7,234,983 Shares are duly tendered to the Fund before the expiration of the Offer and not withdrawn, pursuant to Section 5 "Withdrawal Rights" below, the Fund will accept Shares tendered on or before the Expiration Date for payment on a pro rata basis based on the number of tendered Shares with priority for repurchase requests in the case of the death or disability of a shareholder; provided that the Fund reserves the right in its sole discretion to purchase additional outstanding Shares representing up to 2.0% of the Fund's outstanding Shares without amending or extending the Offer as permitted by Rule 13e-4(f)(1) of the Securities Exchange Act of 1934, as amended. The unaccepted portion of any tender of Shares made by a Shareholder pursuant to this Offer shall not be automatically carried forward or given priority in connection with any future tender offer made by the Fund, but any Shareholder that wishes to have the Fund repurchase Shares that were not accepted for repurchase in connection with this Offer may again tender those Shares in connection with, and subject to the terms and conditions of, any future tender offer made by the Fund.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.<u>Procedure for Tenders</u>. Shareholders wishing to tender Shares pursuant to the Offer must complete and execute the Letter of Transmittal in accordance with the instructions on the first page of such Shareholder's Letter of Transmittal. The completed and executed Letter of Transmittal must be received by the specified agent by 11:59 p.m., Eastern Time, on the Expiration Date.

Submissions may be made by mail at HPS Corporate Lending Fund, c/o U.S. Bank Global Fund Services, 615 East Michigan Street, Milwaukee, WI 53202. The Fund recommends that all documents be submitted by certified mail, return receipt requested.

Shareholders wishing to confirm receipt of a Letter of Transmittal may contact the agent specified in the instructions therein. ***The method of delivery of any documents is at the election and complete risk of the Shareholder tendering Shares, including, but not limited to, the failure to receive any Letter of Transmittal or other document submitted by facsimile transmission.*** All questions as to the validity, form, eligibility (including time of receipt) and acceptance of tenders will be determined by the Fund, in its sole discretion, and its determination shall be final and binding. The Fund reserves the absolute right to reject any or all tenders (i) determined by it not to be in appropriate form or (ii) for which the acceptance of, or payment for, would, in the opinion of counsel for the Fund, be unlawful. The Fund also reserves the absolute right to waive any of the conditions of the Offer or any defect in any tender with respect to any particular Shares or any particular Shareholder (including, without limitation, the conditions relating to the dates on which Shares must be tendered or withdrawn), and the Fund's interpretation of the terms and conditions of the Offer will be final and binding. Unless waived, any defects or irregularities in connection with tenders must be cured within such time as the Fund shall determine. Tenders will not be deemed to have been made until the defects or irregularities have been cured or waived. None of the Fund, the Board, the Adviser, or any of their agents is obligated to give notice of any defects or irregularities in tenders, nor shall any of them incur any liability for failure to give such notice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.<u>Withdrawal Rights</u>. Any Shareholder tendering Shares pursuant to this Offer may withdraw tendered Shares at any time before the Expiration Date or, if the Fund has not accepted such tendered Shares, on or after March 30, 2023. A form to use to give notice of withdrawal is enclosed with the Offer to Purchase. To be effective, any notice of withdrawal must be timely received by the agent specified in the instructions to the Notice of Withdrawal. All questions as to the form and validity (including time of receipt) of notices of withdrawal will be determined by the Fund, in its sole discretion, and such determination shall be final and binding. Shares properly withdrawn shall not thereafter be deemed to be tendered for purposes of the Offer. However, withdrawn Shares may be re-tendered prior to the Expiration Date by following the procedures for tenders described above.

&nbsp;&nbsp;&nbsp;&nbsp;3

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.<u>Purchases and Payment</u>. For purposes of the Offer, the Fund will be deemed to have accepted Shares that are tendered if and when it gives written notice to the tendering Shareholder of its election to purchase such Shares.

If an Investor tenders Shares and the Fund purchases those Shares, the Fund will effect payment for those Shares in cash promptly after the determination of the relevant NAV per share is finalized.

Other than the early repurchase deduction described below (if applicable), the Fund does not expect to impose any charges on repurchases of Shares in the Fund.

Each Shareholder whose Shares (or portion thereof) have been accepted for repurchase will continue to be a Shareholder of the Fund until the Valuation Date (and thereafter if not all of its Shares are repurchased) and may exercise his or her voting rights with respect to the repurchased Shares (or portion thereof) until the Valuation Date.

As described in the Prospectus and except as described below, the amount to which any Shareholder that sells Shares to the Fund in a repurchase offer that has a tender valuation date within the 12-month period following the original issue date of the Shares is entitled to be paid for the tendered Shares will be reduced by 2% of the aggregate net asset value of the Shares repurchased by the Fund; this reduction is referred to herein as an "early repurchase deduction." Payment of the early repurchase deduction will be made by reducing the repurchase proceeds. The early repurchase deduction will be retained by the Fund for the benefit of remaining Shareholders. Shares repurchased will be treated as having been repurchased on a "first in–first out" basis. Therefore, the portion of Shares repurchased will be deemed to have been taken from the earliest Shares purchased by such Shareholder. Shares that are issued pursuant to the Fund's DRIP and tendered, including any portion of Shares repurchased that are issued pursuant to the Fund's DRIP, shall not be subject to the early repurchase deduction.

A Shareholder who tenders some but not all of such Shareholder's Shares for repurchase will be required to maintain a minimum account balance of $1,500 in the Fund. Such minimum account balance requirement may be waived by the Fund, in its sole discretion. The Fund reserves the right to reduce the number of Shares to be repurchased from a Shareholder so that the required account balance is maintained.

The Fund expects that the purchase price for Shares acquired pursuant to the Offer to Purchase will be derived from cash on hand (including cash received from investments in the Fund), borrowings and/or proceeds from the sale of portfolio holdings. Payment for repurchased shares may require the Fund to liquidate portfolio holdings earlier than our Adviser would otherwise have caused these holdings to be liquidated, potentially resulting in losses, and may increase our investment-related expenses as a result of higher portfolio turnover rates. The Fund intends to take measures, subject to policies as may be established by our Board of Trustees, to attempt to avoid or minimize potential losses and expenses resulting from the repurchase of shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.<u>Certain Conditions of the Offer</u>. The Fund reserves the right, at any time and from time to time, to extend the period of time during which the Offer is pending by notifying Shareholders of such extension. If the Fund elects to extend the tender period, the Valuation Date may occur after March 31, 2023 and in that case, for purposes of determining the purchase price for tendered Shares, the net asset value of such Shares will be determined approximately one month after the actual Valuation Date. During any such extension, all Shares previously tendered and not withdrawn will remain subject to the Offer. The Fund also reserves the right, at any time and from time to time, up to and including acceptance of tenders pursuant to the Offer, to: (a) cancel the Offer and in the event of such cancellation, not to purchase or pay for any Shares tendered pursuant to the Offer; (b) amend the Offer; or (c) postpone the acceptance of Shares tendered. If the Fund determines to amend the Offer or to postpone the acceptance of Shares tendered, it will, to the extent necessary, extend the period of time during which the Offer is open as provided above and will promptly notify Shareholders.

Please note that just as you have the opportunity to withdraw shares that you have tendered under certain circumstances, the Fund has the right to cancel, amend or postpone the Offer at any time before accepting tendered Shares. The Fund may cancel the Offer, amend the Offer or postpone the acceptance of tenders

&nbsp;&nbsp;&nbsp;&nbsp;4

------

made pursuant to the Offer if: (a) the Fund would not be able to liquidate portfolio securities in a manner that is orderly and consistent with the Fund's investment objectives and policies in order to purchase Shares tendered pursuant to the Offer; (b) there is, in the Board's judgment, any (i) legal action or proceeding instituted or threatened challenging the Offer or that otherwise would have a material adverse effect on the Fund, (ii) declaration of a banking moratorium by Federal or state authorities or any suspension of payment by banks in the United States or New York State that is material to the Fund, (iii) limitation imposed by Federal or state authorities on the extension of credit by lending institutions, (iv) suspension of trading on any organized exchange or over-the-counter market where the Fund has a material investment, (v) commencement of war, armed hostilities or other international or national calamity directly or indirectly involving the United States that is material to the Fund, (vi) material decrease in the estimated net asset value of the Fund from the estimated net asset value of the Fund as of the commencement of the Offer, or (vii) other event or condition that would have a material adverse effect on the Fund or its Shareholders if Shares tendered pursuant to the Offer were purchased; or (c) the Independent Trustees of the Fund determine that it is not in the best interest of the Fund to purchase Shares pursuant to the Offer. However, there can be no assurance that the Fund will exercise its right to extend, amend or cancel the Offer or to postpone acceptance of tenders pursuant to the Offer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.<u>Certain Information About the Fund</u>. The Fund is a non-diversified, closed-end management investment company that has elected to be regulated as a business development company under the 1940 Act and is organized as a Delaware statutory trust. The principal executive office of the Fund is located at 40 West 57th Street, 33<sup>rd</sup> Floor, New York, NY 10019 and the telephone number is 212-287-6767. Shares are not traded on any established trading market.

The Fund does not have any other plans or proposals that relate to or would result in: (a) the acquisition by any person of additional Shares (other than the Fund's intention to accept purchases for Shares from time to time, the DRIP or otherwise in the discretion of the Fund) or the disposition of Shares (except for periodic discretionary solicitations of tender offers); (b) an extraordinary transaction, such as a merger, reorganization or liquidation, involving the Fund; (c) any material change in the present distribution policy or indebtedness or capitalization of the Fund; (d) any change in the identity of the investment adviser or Trustees of the Fund, or in the management of the Fund including, but not limited to, any plans or proposals to change the number or the term of the Trustees, to change any material term of the investment advisory arrangements with the Adviser; (e) a sale or transfer of a material amount of assets of the Fund (other than as the Trustees determine may be necessary or appropriate to fund any portion of the purchase price for Shares acquired pursuant to this Offer to Purchase or in connection with the ordinary portfolio transactions of the Fund); (f) any other material change in the Fund's structure or business, including any plans or proposals to make any changes in its fundamental investment policy for which a vote would be required by Section 13 of the 1940 Act; or (g) any changes in the Fourth Amended and Restated Declaration of Trust, as amended (the "<u>Declaration of Trust</u>"), Bylaws, or Prospectus or other actions that may impede the acquisition of control of the Fund by any person.

Based on the number of Shares outstanding as of December 31, 2022, the following persons (the named individuals being the Trustees, officers and persons deemed to have a controlling interest in the Adviser) own the number of Shares indicated in the below table:

---

| | | |
|:---|:---|:---|
| **<u>Person</u>** | **<u>Shares</u>** | **<u>Percentage<br>of the Fund's<br>Outstanding Shares</u>** |
| HPS Investment Partners, LLC | 107 | \* |
| Michael Patterson | 199203 | \* |
| Grishma Parekh | 19920 | \* |
| Scott Kapnick<sup>1</sup> | 456000 | \* |

---

\*&nbsp;&nbsp;&nbsp;&nbsp;Less than 1%.

<sup>1</sup> &nbsp;&nbsp;&nbsp;&nbsp;Shares beneficially owned indirectly through various trusts in which Scott Kapnick holds dispositive voting and investment power. Mr. Kapnick is listed because he is deemed to have a controlling interest in the Adviser. The address for Scott Kapnick is c/o HPS Investment Partners, LLC, 40 West 57th Street, 33rd Floor, New York, NY 10019.

&nbsp;&nbsp;&nbsp;&nbsp;5

------

Based on information available to the Fund, none of the persons listed above intends to tender any of his or her Shares in the Offer.

Reference is made to Section 8 "Certain Information About the Fund" of the Offer to Repurchase, which is incorporated herein by reference. During the past sixty (60) days, the Fund has issued to the Adviser, Trustees and officers of the Fund an aggregate of approximately 1.88 shares, including the net impact of shares issued pursuant to the Fund's DRIP, for net proceeds of approximately $45 to the Adviser, any Trustee or officer of the Fund, or any person controlling the Fund or the Adviser. There have been no other transactions in Shares effected during the past sixty (60) days by the Fund, the Adviser, or any Trustee or officer of the Fund, or any person controlling the Fund or the Adviser.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.<u>Full Tender by DRIP Participants</u>. If you are a participant in the DRIP, in the event you elect to tender your Shares in full and such full tender is accepted by the Fund, your participation in the DRIP will be automatically terminated as of the applicable Expiration Date and any distributions due but not yet paid as of such date will be paid in cash on the scheduled distribution payment date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.<u>Certain Federal Income Tax Consequences</u>. The following discussion is a general summary of the U.S. federal income tax consequences of the purchase of Shares by the Fund from Shareholders pursuant to the Offer. This summary is based on U.S. federal income tax law as of the date hereof, including the Internal Revenue Code of 1986, as amended (the "<u>Code</u>"), applicable Treasury regulations, Internal Revenue Service ("<u>IRS</u>") rulings, judicial authority and current administrative rulings and practice, all of which are subject to change, possibly with retroactive effect. There can be no assurance that the IRS would not assert, or that a court would not sustain, a position contrary to any of those set forth below, and the Fund has not obtained, nor does the Fund intend to obtain, a ruling from the IRS or an opinion of counsel with respect to any of the consequences described below. For more detailed information regarding tax considerations applicable to a purchase of Shares by the Fund pursuant to the Offer, and ownership of Shares of the Fund in general, see the Fund's Prospectus. Shareholders should also consult their own tax advisers regarding their particular situation and the potential tax consequences to them of a purchase of their Shares by the Fund pursuant to the Offer, including potential state, local and foreign taxation, as well as any applicable transfer taxes.

Except where noted, this discussion deals only with Shares held as capital assets and does not deal with all tax consequences that may be relevant to Shareholders in light of their particular circumstances or to Shareholders subject to special tax rules (including, without limitation, partnerships or other pass-through entities (and investors therein), dealers or traders in securities, financial institutions, tax-exempt organizations, insurance companies, U.S. expatriates, persons liable for the alternative minimum tax, persons holding Shares as a part of a hedging, conversion or constructive sale transaction or a straddle, nonresident alien individuals present in the United States for more than 182 days during the taxable year in which their Shares are repurchased pursuant to the Offer or U.S. Shareholders (as defined below) whose functional currency is not the U.S. dollar). In addition, this discussion does not address any considerations in respect of any withholding required pursuant to the Foreign Account Tax Compliance Act of 2010 (including the Treasury regulations promulgated thereunder and intergovernmental agreements entered into in connection therewith).

As used herein, the term "U.S. Shareholder" refers to a Shareholder who is (i) an individual citizen or resident of the United States, (ii) a corporation created or organized in or under the laws of the United States or any State thereof or the District of Columbia, (iii) an estate the income of which is subject to U.S. federal income tax regardless of the source of such income, or (iv) a trust if (a) a court within the United States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons (as defined in the Code) have the authority to control all substantial decisions of the trust or (b) the trust has a valid election in effect under applicable Treasury regulations to be treated as a U.S. person. The term "Non-U.S. Shareholder" refers to a Shareholder who is an individual, corporation, estate or trust and is not a U.S. Shareholder. Except for the discussion under "Non-U.S. Shareholders" and "Backup Withholding," the following discussion is limited to U.S. Shareholders.

<u>Sale or Exchange of Shares</u>. Under Section 302(b) of the Code, a Shareholder (other than a tax-exempt Shareholder) whose Shares are repurchased pursuant to the Offer generally will be treated as having sold

&nbsp;&nbsp;&nbsp;&nbsp;6

------

the Shares and will recognize gain or loss for U.S. federal income tax purposes, so long as either (a) such Shareholder tenders, and the Fund repurchases, all of such Shareholder's Shares (i.e., reduces such Shareholder's percentage ownership of the Fund to 0%), (b) such Shareholder meets numerical safe harbors with respect to percentage voting interest and reduction in ownership of the Fund following the completion of the Offer for the distribution to be "substantially disproportionate" with respect to such Shareholder, or (c) the tender otherwise results in a distribution that is "not essentially equivalent to a dividend," which determination depends on a Shareholder's particular facts and circumstances, including the initial size of and extent to which a Shareholder's ownership percentage interest in the Fund is reduced. For these purposes, a shareholder's ownership of the Fund is determined after applying the ownership attribution rules under Section 318 of the Code. The gain or loss recognized by a Shareholder in such case generally will equal the difference between the price paid by the Fund for the Shares pursuant to the Offer and the Shareholder's adjusted tax basis in the Shares sold. A tendering Shareholder's gain or loss will generally be capital gain or loss, and will generally be treated as long-term capital gain or loss if the Shares have been held for more than one year or as short-term capital gain or loss if the Shares have been held for one year or less. For these purposes, a Shareholder's holding period in Shares repurchased pursuant to the Offer should terminate as of the Valuation Date. If a Shareholder realizes a gain upon the sale of its Shares and payment for the Shares is received after the close of the taxable year of the Shareholder in which the Valuation Date occurs, it is expected that, unless the Shareholder elects otherwise, the Shareholder will generally recognize such gain in the taxable year in which the proceeds are received. The maximum U.S. federal income tax rate applicable to short-term capital gains recognized by a non-corporate Shareholder is currently the same as the applicable ordinary income rate. In addition, the Code generally imposes a 3.8% Medicare contribution tax on the net investment income of certain individuals, estates and trusts to the extent their income exceeds certain threshold amounts. For these purposes, "net investment income" generally includes, among other things, (i) distributions paid by the Fund of net investment income and capital gains, and (ii) any net gain from the sale, exchange or other taxable disposition of the Shares.

In the event that a tendering Shareholder's ownership (taking into account deemed ownership under Section 318 of the Code) of Shares of the Fund is not reduced to the extent required under the tests described above, such Shareholder would be deemed to receive a distribution from the Fund under Section 301 of the Code with respect to the Shares held by the Shareholder after the tender (a "<u>Section 301 distribution</u>"). Such distribution, which would equal the price paid by the Fund to such Shareholder for the Shares sold, would be taxable as a dividend to the extent of the Fund's current or accumulated earnings and profits allocable to such Shareholder, with the excess treated as a return of capital reducing the Shareholder's tax basis in the Shares, and thereafter as capital gain. If any amounts received by a Shareholder are treated as a dividend, the tax basis (after any adjustment for a return of capital) in the Shares sold pursuant to the Offer will generally be transferred to any remaining Shares held by the Shareholder. It is not expected that any amount treated as a dividend will be eligible for the dividends received deduction allowed to corporations or for the reduced U.S. federal income tax rates that are currently imposed on certain "qualified dividend income" received by non-corporate Shareholders.

Provided that no tendering Shareholder is treated as receiving a Section 301 distribution as a result of the Offer, Shareholders whose percentage ownership of the Fund increases as a result of the Offer will not be treated as realizing constructive distributions by virtue of that increase. In the event that any tendering Shareholder is deemed to receive a Section 301 distribution as a result of the Offer, it is possible that Shareholders whose percentage ownership of the Fund increases as a result of the Offer, including Shareholders who do not tender any Shares pursuant to the Offer, will be deemed to receive a constructive distribution under Section 305(c) of the Code in an amount determined by the increase in their percentage ownership of the Fund as a result of the Offer. Such constructive distribution will be treated as a dividend to the extent of the Fund's current or accumulated earnings and profits allocable to it.

Under the "wash sale" rules under the Code, provided the tender of Shares pursuant to the Offer is treated as a sale or exchange (and not a distribution as described above), loss recognized on Shares sold pursuant to the Offer will ordinarily be disallowed to the extent the Shareholder acquires other Shares of the Fund (whether through automatic reinvestment of dividends or otherwise) or substantially identical stock or securities within 30 days before or after the date the tendered Shares are purchased pursuant to the Offer. In that event, the basis and holding period of the Shares (or substantially identical stock or securities) acquired will be adjusted to reflect the disallowed loss. Any loss realized by a Shareholder on the sale of

&nbsp;&nbsp;&nbsp;&nbsp;7

------

Shares held by the Shareholder for six months or less will be treated for U.S. federal income tax purposes as a long-term capital loss to the extent of any distributions or deemed distributions of long-term capital gains received by the Shareholder with respect to such Shares. A Shareholder's ability to utilize capital losses may be limited under the Code.

<u>Non-U.S. Shareholders</u>. Generally, if a Non-U.S. Shareholder's sale of Shares pursuant to the Offer is respected as a sale or exchange for U.S. federal income tax purposes pursuant to Section 302(b) of the Code (as discussed above), any gain realized by the Non-U.S. Shareholder will not be subject to U.S. federal income tax or to any U.S. tax withholding, provided that such gain is not effectively connected with a trade or business carried on in the United States by the Non-U.S. Shareholder. If, however, all or a portion of the proceeds received by a tendering Non-U.S. Shareholder is treated for U.S. federal income tax purposes as a distribution by the Fund that is a dividend, or if a Non-U.S. Shareholder is otherwise treated as receiving a deemed distribution that is a dividend by reason of the Shareholder's increase in its percentage ownership of the Fund resulting from other Shareholders' sale of Shares pursuant to the Offer, and, as discussed in greater detail in the Fund's Prospectus, absent a statutory exemption, the dividend received or deemed received by the Non-U.S. Shareholder will be subject to a U.S. withholding tax of 30% (or a lower treaty rate). If any gain or dividend income realized in connection with the tender of Shares by a Non-U.S. Shareholder is effectively connected with a trade or business carried on in the United States by the Non-U.S. Shareholder, such gain or dividend will generally be taxed at the regular rates applicable to U.S. Shareholders. In addition, if the Non-U.S. Shareholder is a non-U.S. corporation, it may be subject to a branch profits tax of 30% (or a lower treaty rate) on its effectively connected income. In order to qualify for an exemption from withholding for effectively connected income or for lower withholding tax rates under income tax treaties, or to establish an exemption from backup withholding, a Non-U.S. Shareholder must comply with special certification and filing requirements relating to its non-U.S. status (including, in general, furnishing an IRS Form W-8ECI, W-8BEN or W-8BEN-E, as applicable, or any substitute form). Because an applicable withholding agent may not be able to determine if a particular Non-U.S. Shareholder qualifies for sale or exchange treatment pursuant to Section 302(b) of the Code, such agent may withhold U.S. federal income tax equal to 30% of the gross payments payable to a Non-U.S. Shareholder unless the agent determines that an exemption or a reduced rate of withholding is available as discussed above. However, a Non-U.S. Shareholder may be eligible to obtain a refund of all or a portion of any tax withheld if such Non-U.S. Shareholder establishes that it qualifies for sale or exchange treatment pursuant to Section 302(b) of the Code or is otherwise able to establish that no tax or a reduced amount of tax is due. See the section of the Fund's Prospectus entitled "Certain U.S. Federal Income Tax Considerations–Foreign Shareholders" for further information concerning the taxation of Non-U.S. Shareholders. Non-U.S. Shareholders are urged to consult their tax advisors regarding the application of U.S. federal income tax rules, including withholding, to their tender of Shares.

<u>Backup Withholding</u>. The Fund generally is required to withhold and remit to the U.S. Treasury a percentage of the taxable distributions and redemption proceeds paid to any U.S. Shareholder who fails to properly furnish the Fund with a correct taxpayer identification number and a certification that such Shareholder is not subject to backup withholding (generally, through the provision of a properly executed IRS Form W-9). A Non-U.S. Shareholder generally can establish an exemption from backup withholding by certifying as to its foreign status (generally, through the provision of a properly executed IRS Form W-8BEN, W-8BEN-E or other applicable Form W-8).

Shareholders should provide the Fund with a completed IRS Form W-9, W-8BEN or W-8BEN-E, as applicable, or other appropriate form in order to avoid backup withholding on the payment they receive from the Fund regardless of how they are taxed with respect to their tendered Shares. Backup withholding is not an additional tax and any amount withheld may be credited against a Shareholder's U.S. federal income tax liability, and may entitle the Shareholder to a refund, provided in each case that the appropriate information is furnished to the IRS.

<u>Other Tax Consequences</u>. The Fund's purchase of Shares in the Offer may directly result in, or contribute to a subsequent, limitation on the Fund's ability to use capital loss carryforwards to offset future gains. Therefore, in certain circumstances, Shareholders who remain Shareholders following completion of the Offer may pay taxes sooner, or pay more taxes, than they would have had the Offer not occurred.

&nbsp;&nbsp;&nbsp;&nbsp;8

------

Payments for repurchased Shares may require the Fund to liquidate all or a portion of its portfolio holdings. Such action could give rise to increased taxable distributions to Shareholders, including distributions of ordinary income or short-term capital gains taxable to individuals as ordinary income.

Under Treasury regulations directed at tax shelter activity, if a Shareholder recognizes a loss of $2 million or more for an individual Shareholder or $10 million or more for a corporate Shareholder, such Shareholder must file with the IRS a disclosure statement on Form 8886. Direct holders of portfolio securities are in many cases excepted from this reporting requirement, but under current guidance, shareholders of a regulated investment company ("<u>RIC</u>"), such as the Fund, are not excepted. Future guidance may extend the current exception from this reporting requirement to shareholders of most or all RICs. The fact that a loss is reportable under these regulations does not affect the legal determination of whether the taxpayer's treatment of the loss is proper. Shareholders should consult their own tax advisers concerning any possible disclosure obligation with respect to their disposition of Shares pursuant to the Offer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.<u>Miscellaneous</u>. The Offer is not being made to, nor will tenders be accepted from, Shareholders in any jurisdiction in which the Offer or its acceptance would not comply with the securities or Blue Sky laws of such jurisdiction. The Fund is not aware of any jurisdiction in which the Offer or tenders pursuant thereto would not be in compliance with the laws of such jurisdiction. However, the Fund reserves the right to exclude Shareholders from the Offer in any jurisdiction in which it is asserted that the Offer cannot lawfully be made. The Fund believes such exclusion is permissible under applicable laws and regulations, provided the Fund makes a good faith effort to comply with any state law deemed applicable to the Offer.

The Fund has filed an Issuer Tender Offer Statement on Schedule TO with the Securities and Exchange Commission (the "<u>SEC</u>"), which includes certain information relating to the Offer summarized herein. A free copy of such statement may be obtained from the Fund at www.hlend.com, by contacting the Transfer Agent at (888) 484-1944, or from the SEC's internet web site, http://www.sec.gov.

**FINANCIAL STATEMENTS**

The audited annual financial statements of the Fund dated December 31, 2021 filed with the SEC on EDGAR on January 26, 2022, are incorporated by reference. The Fund will prepare and make available to Shareholders the audited annual financial statements of the Fund within 90 days after the close of the period for which the report is being made, or as otherwise required by the 1940 Act.

&nbsp;&nbsp;&nbsp;&nbsp;9

## Ex-99.(A)(1)(Iii)

**Exhibit (a)(1)(iii)** 

***Letter of Transmittal***

***Regarding Shares in HPS Corporate Lending Fund***

***Tendered Pursuant to the Offer to Purchase***

***Dated February 2, 2023***

*The Offer and withdrawal rights will expire on March 2, 2023* 

*and this Letter of Transmittal must be received by* 

*the Fund's Transfer Agent by mail by 11:59 p.m.,* 

*Eastern Time, on March 2, 2023, unless the Offer is extended* 

*Complete this Letter of Transmittal and follow the Transmittal* 

*Instructions included herein* 

Ladies and Gentlemen:

The undersigned hereby tenders to HPS Corporate Lending Fund, a non-diversified, closed-end management investment company that has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended (the "1940 Act") and is organized as a Delaware statutory trust (the "Fund"), the shares of beneficial interest in the Fund or portion thereof held by the undersigned, described and specified below, on the terms and conditions set forth in the Offer to Purchase dated February 2, 2023 (the "Offer to Purchase"), receipt of which is hereby acknowledged, and in this Letter of Transmittal (which together with the Offer to Purchase constitute the "Offer"). *The Tender and this Letter of Transmittal are subject to all the terms and conditions set forth in the Offer to Purchase, including, but not limited to, the absolute right of the Fund to reject any and all tenders determined by it, in its sole discretion, not to be in the appropriate form.*

The undersigned hereby sells to the Fund the shares of beneficial interest in the Fund or portion thereof tendered hereby pursuant to the Offer.

The undersigned hereby warrants that the undersigned has full authority to sell the shares of beneficial interest in the Fund or portion thereof tendered hereby and that the Fund will acquire good title thereto, free and clear of all liens, charges, encumbrances, conditional sales agreements or other obligations relating to the sale thereof, and not subject to any adverse claim, when and to the extent the same are purchased by it. Upon request, the undersigned will execute and deliver any additional documents necessary to complete the sale in accordance with the terms of the Offer. The undersigned recognizes that under certain circumstances set forth in the Offer, the Fund may not be required to purchase any of the beneficial shares of interest in the Fund or portions thereof tendered hereby.

A non-transferable, non-interest bearing promissory note for the purchase price will be issued to the undersigned if the Fund accepts for purchase the shares tendered hereby. The undersigned acknowledges that U.S. Bancorp Fund Services, LLC (d/b/a U.S. Bank Global Fund Services), the Fund's transfer agent, will hold the promissory note on behalf of the undersigned. The cash payment(s) of the purchase price for the shares of beneficial interest in the Fund or portion thereof of the undersigned, as described in Section 6 "Purchases and Payment" of the Offer to Purchase, shall be wired to the account from which your subscription funds were debited.

All authority herein conferred or agreed to be conferred shall survive the death or incapacity of the undersigned and the obligation of the undersigned hereunder shall be binding on the heirs, personal representatives, successors and assigns of the undersigned. Except as stated in Section 5 "Withdrawal Rights" of the Offer to Purchase, this tender is irrevocable.

------

**<u>VALUATION DATE</u>: March 31, 2023** 

**<u>TENDER OFFER EXPIRATION DATE</u>: 11:59 p.m. (Eastern Time), March 2, 2023** 

**PARTS 1, 2, 3, AND 4 MUST BE COMPLETED AND IN GOOD ORDER IN ORDER TO PROCESS YOUR REQUEST** 

**If You Invest In The Fund Through A Financial Intermediary Through Whom You Expect To Have Your Tender Offer Request Submitted, Please Allow For Additional Processing Time As The <u>Letter of Transmittal Must Ultimately Be Received By The Fund's Transfer Agent No Later Than 11:59 p.m. (Eastern Time) On The Expiration Date</u>.** 

**PLEASE SEND COMPLETED FORMS TO:**

**HPS Corporate Lending Fund<br>c/o U.S. Bank Global Fund Services<br>615 East Michigan Street<br>Milwaukee, WI 53202**

**PART 1 – NAME (AS IT APPEARS ON YOUR HPS CORPORATE LENDING FUND STATEMENT) AND CONTACT INFORMATION** 

---

| |
|:---|
| Fund Name: |
| Fund Account #: |
| Account Name/Registration: |
| Address: |
| City, State, Zip |
| Telephone Number: |
| Email Address: |
| Financial Intermediary Firm Name: |
| Financial Intermediary Account #: |
| Financial Advisor Name: |
| Financial Advisor Telephone #: |

---

**PART 2 – REQUESTED TENDER AMOUNT** 

**Please select repurchase type by checking one of the boxes below. If you are requesting a partial repurchase, please provide a number of Shares.** 

<br> ☐ Full Repurchase

☐ Partial Repurchase\* of Class I Shares (__________________________ Shares)

☐ Partial Repurchase\* of Class D Shares (__________________________ Shares)

☐ Partial Repurchase\* of Class F Shares (__________________________ Shares)

 \* If the requested partial repurchase would put the account balance below the required minimum balance, the Fund may reduce the amount to be repurchased such that the required minimum balance is maintained, unless you indicate otherwise by checking the following box:

 ☐ Change request to Full Repurchase if amount requested to be repurchased would need to be reduced to maintain minimum account balance

------

**HPS CORPORATE LENDING FUND ACCOUNT #: (Should be the same as on page 2)** 

**PART 3 – PAYMENT** 

Payments will be directed back to the account from which your subscription funds were debited. Contact your financial intermediary or account manager if you have any questions.

**PART 4 – SIGNATURE(S)** 

The undersigned subscriber acknowledges that this request is subject to all the terms and conditions set forth in the Fund's Prospectus and the Offer to Purchase dated February 2, 2023 (the "Offer to Purchase") and all capitalized terms used herein have the meaning as defined in the Fund's Prospectus. This request is irrevocable except as described in the Offer to Purchase. The undersigned represents that the undersigned is the beneficial owner of the shares in the Fund to which this repurchase request relates, or that the person signing this request is an authorized representative of the tendering shareholder.

In the case of joint accounts, each joint holder must sign this repurchase request. Requests on behalf of a foundation, partnership or any other entity should be accompanied by evidence of the authority of the person(s) signing.

---

| | | |
|:---|:---|:---|
| Signature | Print Name of Authorized Signatory (and Title if applicable) | Date |
| Signature | Print Name of Authorized Signatory (and Title if applicable) | Date |

---

## Ex-99.(A)(1)(Iv)

**Exhibit (a)(1)(iv)**

**Form of Letter from the Fund to Shareholders<br>in Connection with the Fund's Acceptance of Shares**

HPS Corporate Lending Fund<br>c/o U.S. Bank Global Fund Services<br>615 East Michigan Street<br>Milwaukee, WI 53202

[DATE]

[SHAREHOLDER NAME/ADDRESS]

Dear Shareholder:

This letter serves to inform you that HPS Corporate Lending Fund (the "<u>Fund</u>") has received and accepted for purchase your tender of shares of beneficial interest in the Fund.

In accordance with the terms of the tender offer, you will be issued a non-interest bearing, non-transferable promissory note (the "<u>Note</u>"), which will be held on your behalf by U.S. Bancorp Fund Services, LLC (d/b/a U.S. Bank Global Fund Services), the Fund's transfer agent ("<u>Transfer Agent</u>"), entitling you to receive payment(s) in an aggregate amount equal to the net asset value of the tendered shares as of March 31, 2023 less the 2% "early repurchase deduction" (if applicable).

If you have any questions (or wish to request a copy of your Note), please contact the Fund's Transfer Agent at (888) 484-1944.

Sincerely,

HPS Corporate Lending Fund

## Ex-99.(A)(1)(V)

**Exhibit (a)(1)(v)**

**Form of Promissory Note for Repurchases of your Shares**

**HPS CORPORATE LENDING FUND**

Dated: [insert date]

FOR VALUE RECEIVED, HPS Corporate Lending Fund ("<u>Payor</u>" or the "<u>Company</u>"), a Delaware statutory trust issuing its shares of beneficial interest ("<u>Shares</u>"), hereby promises to pay [insert name of payee] ("<u>Payee</u>") the Payment Amount (as defined in Section 2) in a single installment as discussed below.

This Note is being issued so that Payor may purchase Shares (the "<u>Repurchased Shares</u>") from Payee pursuant to the terms and subject to the conditions set out in the Offer to Purchase dated February 2, 2023 and the Letter of Transmittal submitted by the Payee (which Offer to Purchase and Letter of Transmittal, together with any amendments or supplements thereto collectively constitute the "<u>Offer</u>"). This Note is not negotiable and is not interest-bearing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.<u>General Payment Provisions</u>. The Payor will pay the Payment Amount under this Note in a single installment in such currency of the United States of America as will be legal tender at the time of payment. Payment under this Note will be made by wire transfer to Payee's account at Payee's authorized agent as previously identified to Payor by Payee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.<u>Payment</u>. The "<u>Payment Amount</u>" will be an amount equal to the value of the Repurchased Shares determined as of March 31, 2023 (the "<u>Valuation Date</u>") reduced by the Early Repurchase Deduction (as defined herein), if applicable. Unless the existence of changes in tax or other laws or regulations or unusual market conditions result in a delay, the Payor will make payment under this Note on or before 35 days after the Valuation Date.

Except as described below, Repurchased Shares that were purchased in a tender offer with a Valuation Date that is within the 12-month period following the initial issue date of such Shares being tendered are subject to an "early repurchase deduction" (the "<u>Early Repurchase Deduction</u>") at a rate of 2% of the aggregate net asset value of such Shares. Repurchased Shares that are issued pursuant to the Company's distribution reinvestment plan and purchased in a tender offer shall not be subject to the Early Repurchase Deduction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.<u>Optional Prepayment</u>. This Note may be prepaid, without premium, penalty or notice, at any time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.<u>Events of Default</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)The occurrence of any of the following events shall be deemed to be an "<u>Event of Default</u>" under this Note:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)The Payor defaults in payment when due and any such default continues for a period of ten (10) days; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)(1) The Payor commences any proceeding or other action relating to the Company in bankruptcy or seeks reorganization, arrangement, readjustment, dissolution, liquidation, winding-up, relief or composition of the Company or the debts of the Company under any law relating to bankruptcy, insolvency or reorganization or relief of debtors; (2) the Payor applies for, or consents or acquiesces to, the appointment of a receiver, conservator, trustee or similar officer for the Company or for all or substantially all of the property of the Company; (3) the Payor makes a general assignment for the benefit of creditors of the Company; or (4) the Payor generally admits its inability to pay its debts with respect to the Company as they become due and payable; or

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)(1) The commencement of any proceeding or the taking of any other action against the Company in bankruptcy or seeking reorganization, arrangement, readjustment, dissolution, liquidation, winding-up, relief or composition of the Company or the debts of the Company under any law relating to bankruptcy, insolvency or reorganization or relief of debtors and the continuance of any of such events for sixty (60) days undismissed, unbonded or undischarged; or (2) the appointment of a receiver, conservator, trustee or similar officer for the Payor or for all or substantially all of the property of the Company and the continuance of any such event for sixty (60) days undismissed, unbonded or undischarged.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Upon the occurrence of an Event of Default, the entire unpaid amount of this Note outstanding shall become immediately due and payable, without presentment, demand, protest, or other notice of any kind, all of which are expressly waived, and without any action on the part of the Payee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.<u>Miscellaneous</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)<u>Governing Law; Consent to Jurisdiction</u>. This Note and the rights and remedies of the Payor and Payee will be governed by and construed in accordance with the laws of the State of New York applicable to agreements made and to be wholly performed within such State, without regard to the conflict of laws principles of such State. Any legal action, suit or proceeding arising out of or relating to this Agreement may be instituted in any state or federal court located within the County of New York, State of New York, and each party hereto agrees not to assert, by way of motion, as a defense, or otherwise, in any such action, suit or proceeding, any claim that it is not subject personally to the jurisdiction of such court, that the venue of the action, suit or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)<u>Notices</u>. All communications under this Note will be given in writing, sent by telecopier or registered mail to the address set forth below or to such other address as such party will have specified in writing to the other party hereto, and will be deemed to have been delivered effective at the earlier of its receipt or within two (2) days after dispatch.

If to Payor, to:&nbsp;&nbsp;&nbsp;&nbsp;HPS Corporate Lending Fund<br>40 West 57th Street, 33rd Floor,

New York, NY 10019

Telephone: (212) 587-6767<br>Attention: Tyler Thorn

If to Payee, to:&nbsp;&nbsp;&nbsp;&nbsp;[Insert contact information for the Payee]

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)<u>Severability, Binding Effect</u>. Any provision of this Note that is prohibited or unenforceable in any jurisdiction will, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction will not invalidate or render unenforceable such provision in any other jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)<u>Amendment; Waiver</u>. No provision of this Note may be waived, altered or amended, except by written agreement between the Payor and Payee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)<u>Waiver of Presentment</u>. Payor hereby waives presentment, protest, demand for payment and notice of default or nonpayment to or upon Payor with respect to this Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)<u>Entire Agreement</u>. This Note and the Offer set out the entire agreement between the parties and supersede any prior oral or written agreement between the parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)<u>Delaware Statutory Trust</u>. The obligations of the Company under this Note are not binding upon any trustee or shareholder of the Company personally, but bind only the Company and the Company's property. A copy of the Amended and Restated Certificate of Trust of the Company is on file with the State of Delaware, and notice is hereby given that this instrument is executed on behalf of the

&nbsp;&nbsp;&nbsp;&nbsp;2

------

trustees of the Company as trustees and not individually and that the obligations of or arising out of this instrument are not binding on any of the trustees, officers or shareholders individually, but are binding only upon the trust property of the Company.

IN WITNESS WHEREOF, Payor has duly caused this Note to be duly executed as of the date first above written.

**HPS CORPORATE LENDING FUND**

By:&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><br>Name: Robert Busch <br>Title: Chief Financial Officer and Principal Accounting Officer

&nbsp;&nbsp;&nbsp;&nbsp;3

## Ex-99.(A)(1)(Vi)

**Exhibit (a)(1)(vi)** 

***Notice of Withdrawal of Tender***

***Regarding Shares in HPS Corporate Lending Fund***

***Tendered Pursuant to the Offer to Purchase***

***Dated February 2, 2023***

*The Offer and withdrawal rights will expire on March 2, 2023* 

*and this Notice of Withdrawal must be received by* 

*the Fund's Transfer Agent by mail by 11:59 p.m.,* 

*Eastern Time, on March 2, 2023, unless the Offer is extended* 

*Complete this Notice of Withdrawal and follow the transmittal* 

*instructions included herein* 

**PLEASE SEND COMPLETED FORMS TO:**

**HPS Corporate Lending Fund<br>c/o U.S. Bank Global Fund Services<br>615 East Michigan Street<br>Milwaukee, WI 53202** 

You are responsible for confirming that this Notice is received timely. If you fail to confirm receipt of this Notice, there can be no assurance that your withdrawal will be honored by the Fund.

Ladies and Gentlemen:

Please withdraw the tender previously submitted by the undersigned in a Letter of Transmittal.

---

| |
|:---|
| Fund Name: _______________________________________________________________________________ |
| Fund Account #: ____________________________________________________________________________ |
| Account Name/Registration: ___________________________________________________________________ |
| Address: ___________________________________________________________________________________ |
| City, State, Zip ______________________________________________________________________________ |
| Telephone Number: __________________________________________________________________________ |
| Email Address: ______________________________________________________________________________ |
| Financial Intermediary Firm Name: ______________________________________________________________ |
| Financial Intermediary Account #: _______________________________________________________________ |
| Financial Advisor Name: ______________________________________________________________________ |
| Financial Advisor Telephone #: _________________________________________________________________ |

---

The undersigned represents that the undersigned is the beneficial owner of the shares in the Fund to which this withdrawal request relates, or that the person signing this request is an authorized representative of the withdrawing shareholder.

In the case of joint accounts, each joint holder must sign this withdrawal request. Requests on behalf of a foundation, partnership or any other entity should be accompanied by evidence of the authority of the person(s) signing.

---

| | | |
|:---|:---|:---|
| Signature | Print Name of Authorized Signatory (and Title if applicable) | Date |
| Signature | Print Name of Authorized Signatory (and Title if applicable) | Date |

---

## Ex-Filing

**EX-FILING FEES** 

**Calculation of Filing Fee Tables**

**SC TO-I** 

(Form Type)

**HPS Corporate Lending Fund** 

**(Name of Issuer)** 

**HPS Corporate Lending Fund** 

**(Name of Person(s) Filing Statement)** 

**Table 1: Transaction Valuation** 

---

| | | | |
|:---|:---|:---|:---|
| | **Transaction**<br>**Valuation** | **Fee**<br>**rate** | **Amount of**<br>**Filing Fee** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fees to Be Paid | $172771394<sup>(1)</sup> | 0.0001102% | $19039.41<sup>(2)</sup> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fees Previously Paid |  |  |  |
| **Total Transaction Valuation** | $172771394<sup>(1)</sup> |  |  |
| **Total Fees Due for Filing** |  |  | $19039.41<sup>(2)</sup> |
| **Total Fees Previously Paid** |  |  |  |
| **Total Fee Offsets** |  |  |  |
| **Net Fee Due** |  |  | $19039.41<sup>(2)</sup> |

---

(1) Calculated as the aggregate maximum purchase price for shares of beneficial interest, based upon the net asset value per share as of December 31, 2022, of $23.88. This amount is based upon the offer to purchase up to 7,234,983 common shares of beneficial interest, par value $0.01 per share, of HPS Corporate Lending Fund.

(2) Calculated at $110.20 per $1,000,000.00 of the Transaction Valuation in accordance with Rule 0-11 under the Securities Exchange Act of 1934, as amended, as modified by Fee Rate Advisory No. 1 for fiscal year 2022.

<br>